Psoriatic arthritis (PsA) is an inflammatory arthropathy associated with cutaneous psoriasis. approximately 2/3 of patients with PsA develop progressive joint destruction, ultimately leading to joint loss and disability. imaging changes in PsA are diverse, with 47% of patients developing more than one joint destruction in the first 2 years of disease onset, and 55% developing more than 5 joints after 10 years of disease onset. Recent studies have shown that Th-17 cells play an important role in immune-mediated severe inflammation and tissue destruction, and that this response can be inhibited by suppressing IL-23, necessary for the growth of Th-17 cells, or IL-17, the major cytokine they produce. Ustekinumab is a human immunoglobulin G1Қ monoclonal antibody that links the IL-12/IL-23 p40 common subunit and thereby inhibits the immune inflammatory response. A study conducted by Professor Arthur Kavanaugh and others from the University of San Diego, California, USA, the results of which were published in a recent issue of ARD, found that ustekinumab inhibited imaging progression in patients with PsA. The trial used a combined analysis of data from the PSUMMIT-1 and PSUMMIT-2 phase III trials, with all subjects in PSUMMIT-1 not having been treated with anti-tumor necrosis factor alpha (TNF-α), while PSUMMIT-2 included both patients who had used anti-TNF-α and those who had not. Changes in imaging in all patients were evaluated using the vdH-S score. PSUMMIT-1 or PSUMMIT-2 All patients had to meet the following criteria: adult patients with active PsA for ≥6 months, with or without DMARDs for more than 3 months and/or with appropriate NSAIDs for more than 4 weeks were enrolled. Active PsA as mentioned here was defined as swelling in ≥5 of 66 joints, tenderness in ≥5 of 68 joints, serum C-reactive protein greater than or equal to 6.0 mg/l, and a current or previous psoriatic rash. Enrolled patients were randomized (1:1:1) into three groups, i.e., a 45 mg group with ustekinumab, a 90 mg group, and a control group, with dosing at weeks 0, 4, and every 12 weeks thereafter. At week 16, patients with less than 5% relief of pressure pain and swollen joints were defined as shedding, while patients in the control group were converted to the 45 mg group, the original 45 mg group to the 90 mg group, and the original 90 mg group remained unchanged. Those controls who did not shed were given ustekinumab 45 mg at weeks 24 and 28 and every 12 weeks thereafter. Imaging progression was assessed at enrollment, week 24, and week 52. The results of the study showed that at week 24, patients treated with ustekinumab (regardless of dose) had significantly less imaging progression than controls. At week 52, patients on ustekinumab continued to have slow imaging progression, while those who started in the control group and then switched to the 45 mg group also showed slower imaging progression. The study found that ustekinumab inhibited imaging progression in patients with PsA.